Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Qilu Pharmaceutical Co., Ltd.

http://en.qilu-pharma.com/

Latest From Qilu Pharmaceutical Co., Ltd.

Asia Deal Watch: Cytokinetics Licenses China Rights For Omecamtiv To Ji Xing

Plus deals involving Sun's SPARC/Visiox, Twist/Sosei, BeiGene, Leads Biolabs, Qilu/Arbutus, Hansoh/Keros, Simcere/Avilex and Cytokinetics/Ji Xing.

Deals Asia Pacific

Entasis Anticipates First FDA Approval Of Pathogen-Specific Antibacterial

With Phase III data showing non-inferiority to colistin, as well as nephrotoxicity superiority, Entasis thinks sulbactam/durlobactam will provide a new standard of care and succeed where Achaogen’s Zemdri failed.

Clinical Trials Drug Approval Standards

BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue

The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.

China Commercial

Chinese Investors Wary Of In-Licensing-Only Biotechs After IPO Setback

The torpedoed IPO application of a Shanghai-based biotech has already triggered a ripple of unease among venture capitalists in China, with some signaling suspension of investment in similar ventures.

China Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register